The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
News|Articles|November 10, 2015
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-12-02-2015
- Volume 11
- Issue 12
GRAM Adds Board Member
Author(s)Pharmaceutical Technology Editors
Industry veteran Mark Kontny joins board of directors at Grand River Aseptic Manufacturing.
Advertisement
The Grand River Aseptic Manufacturing (GRAM) announced on Nov. 10 2015 that industry veteran Mark Kontny was elected as a member of the the board of directors.
Most recently, Kontny served as president, Pharmaceutical Development Services and chief scientific officer for Patheon. Previously, he served as divisional vice president for Abbott Laboratories, responsible for divisional staffs in Illinois, Massachusetts, Germany, and Singapore. Earlier in his career, Mark spent 10 years at Boehringer Ingelheim, working with the pre-formulation, formulation, and manufacturing of different dosage forms. He became senior director at Pfizer and helped develop small molecules and biologics in both solid-dose and parenteral forms. He worked with a biotech start-up, prior to joining Abbott.
Articles in this issue
almost 11 years ago
Software Corrects Spectra Dataalmost 11 years ago
Lab Reactor Designed for Scale-upalmost 11 years ago
Instrument Measures Endotoxins at Point of Usealmost 11 years ago
Instrument Manufacturers Collaborate on Interoperabilityalmost 11 years ago
HTS Reader Features Three Light Sourcesalmost 11 years ago
“A Hit for Every Target” and Changing the Model for Pharma Innovationalmost 11 years ago
Researchers Identify Advances for Heterocyclic Chemistryalmost 11 years ago
CMOs Lead Ongoing Drive for Single-Use Adoptionalmost 11 years ago
System Automates Traceabilityalmost 11 years ago
Lufthansa Cargo Offers CSafe ContainersAdvertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
Advertisement
Advertisement